Adamas Pharmaceuticals Inc.

2.56-0.0400-1.54%Vol 179.26K1Y Perf -57.42%
Jul 7th, 2020 16:00 DELAYED
BID2.51 ASK2.57
Open2.62 Previous Close2.60
Pre-Market- After-Market2.56
 - -%  - -%
Target Price
6.58 
Analyst Rating
Moderate Buy 1.71
Potential %
157.03 
Finscreener Ranking
★★★+ —    -
Insiders Trans % 3/6/12 mo.
-/-100/-100 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-100/-100 
Growth Ranking
★★★     51.36
Insiders Shares Cnt. % 3/6/12 mo.
-/-100/-100 
Income Ranking
 —    -
Market Cap72.08M 
Earnings Rating
Strong Buy
Price Range Ratio 52W %
11.22 
Earnings Date
13th Aug 2020

Today's Price Range

2.532.65

52W Range

1.907.78

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-5.88%
1 Month
-21.23%
3 Months
-16.07%
6 Months
-49.90%
1 Year
-57.42%
3 Years
-85.71%
5 Years
-90.35%
10 Years
-

TickerPriceChg.Chg.%
ADMS2.56-0.0400-1.54
AAPL372.69-1.1600-0.31
GOOG1 485.18-10.5200-0.70
MSFT208.25-2.4500-1.16
XOM43.24-1.1500-2.59
WFC24.46-1.0300-4.04
JNJ142.85-0.1300-0.09
FB240.860.58000.24
GE6.76-0.2400-3.43
JPM92.32-2.6800-2.82
Financial StrengthValueIndustryS&P 500US Markets
5.10
5.60
0.87
6.80
-5.20
Leverage Ratio -18.30
ProfitabilityValueIndustryS&P 500US Markets
95.40
-134.40
-132.60
-6 010.30
-
RevenueValueIndustryS&P 500US Markets
44.76M
1.59
544.51
58.25
Earnings HistoryEstimateReportedSurprise %
Q01 2020-0.75-0.5921.33
Q04 2019-0.89-0.836.74
Q03 2019-0.90-0.99-10.00
Q02 2019-0.98-0.908.16
Q01 2019-1.13-1.084.42
Q04 2018-1.36-1.0622.06
Q03 2018-1.34-1.228.96
Q02 2018-1.41-1.2610.64
Earnings Per EndEstimateRevision %Trend
6/2020 QR-0.606.25Positive
9/2020 QR-0.53-17.78Negative
12/2020 FY-2.11-0.96Negative
12/2021 FY-1.38-0.73Negative
Next Report Date13th Aug 2020
Estimated EPS Next Report-0.60
Estimates Count6
EPS Growth Next 5 Years %-
Volume Overview
Volume179.26K
Shares Outstanding28.16M
Trades Count1.36K
Dollar Volume516.19K
Avg. Volume453.25K
Avg. Weekly Volume369.64K
Avg. Monthly Volume570.04K
Avg. Quarterly Volume467.50K

Adamas Pharmaceuticals Inc. (NASDAQ: ADMS) stock closed at 2.56 per share at the end of the most recent trading day (a -1.54% change compared to the prior day closing price) with a volume of 180.26K shares and market capitalization of 72.08M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 134 people. Adamas Pharmaceuticals Inc. CEO is Neil McFarlane.

The one-year performance of Adamas Pharmaceuticals Inc. stock is -57.42%, while year-to-date (YTD) performance is -32.45%. ADMS stock has a five-year performance of -90.35%. Its 52-week range is between 1.9 and 7.78, which gives ADMS stock a 52-week price range ratio of 11.22%

Adamas Pharmaceuticals Inc. currently has a PE ratio of -, a price-to-book (PB) ratio of 7.28, a price-to-sale (PS) ratio of 1.64, a price to cashflow ratio of 23.20, a PEG ratio of 2.32, a ROA of -50.16%, a ROC of -50.01% and a ROE of -383.56%. The company’s profit margin is -%, its EBITDA margin is -132.60%, and its revenue ttm is $44.76 Million , which makes it $1.59 revenue per share.

Of the last four earnings reports from Adamas Pharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.60 for the next earnings report. Adamas Pharmaceuticals Inc.’s next earnings report date is 13th Aug 2020.

The consensus rating of Wall Street analysts for Adamas Pharmaceuticals Inc. is Moderate Buy (1.71), with a target price of $6.58, which is +157.03% compared to the current price. The earnings rating for Adamas Pharmaceuticals Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Adamas Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Adamas Pharmaceuticals Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 13.86, ATR14 : 0.19, CCI20 : -77.42, Chaikin Money Flow : 0.07, MACD : -0.08, Money Flow Index : 44.93, ROC : -8.90, RSI : 43.90, STOCH (14,3) : 23.64, STOCH RSI : 0.42, UO : 43.98, Williams %R : -76.36), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Adamas Pharmaceuticals Inc. in the last 12-months were: Alfred G. Merriweather (Sold 1 584 shares of value $10 945 ), Christopher B. Prentiss (Sold 4 702 shares of value $28 009 ), David L. Mahoney (Option Excercise at a value of $58 498)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (71.43 %)
5 (71.43 %)
5 (71.43 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (14.29 %)
1 (14.29 %)
1 (14.29 %)
Moderate Sell
1 (14.29 %)
1 (14.29 %)
1 (14.29 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.71
Moderate Buy
1.71
Moderate Buy
1.71

Adamas Pharmaceuticals Inc.

Adamas Pharmaceuticals Inc discovers, develops, and sells therapies for chronic neurologic disorders. The company's approved/commercial product is GOCOVRI, an amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. It operates in one reportable segment: the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company generates its revenues primarily from the United States.

CEO: Neil McFarlane

Teplephone: +1 510 450-3500

Address: 1900 Powell Street, Emeryville 94608, CA, USA

Number of employees: 134

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

100%0%

Bearish Bullish

33%67%

Bearish Bullish

31%69%

Bearish Bullish

45%55%

News

Stocktwits